Original research
Feasibility and effect of a physical activity counselling session with or without provision of an activity tracker on maintenance of physical activity in women with breast cancer — A randomised controlled trial

https://doi.org/10.1016/j.jsams.2019.09.019Get rights and content

Abstract

Objectives

The SAFE-Maintain study sought to evaluate the effect and acceptability of a physical activity counselling (PAC) session, versus a PAC session plus provision of a Fitbit (Charge HR®; PAC + F), on maintenance of physical activity levels 12 weeks following participation in a supervised exercise intervention.

Design

Fifty-two women with stage II + breast cancer who had recently (within the previous 7 days) completed a 12-week supervised exercise program were randomised to the PAC or PAC + F group.

Methods

Physical activity levels, including weekly minutes of total physical activity (min/week), daily step count (steps/day), and weekly minutes of moderate to vigorous physical activity (MVPA, min/week), were assessed using the Active Australia survey and Actigraph® GT3X+ accelerometers. Self-reported outcomes were assessed at baseline and 12-week follow-up, while objectively-measured outcomes were only available at 12-week follow-up.

Results

Compared with the PAC group, the PAC + F group had higher self-reported MVPA and self-reported total activity (between-group mean difference: 78.2 [95% CI = −8.3, 164.9] min/week, p < 0.01, and 171.9 [95% CI = 46.1, 297.8] min/week, p < 0.01, respectively) at 12-week follow-up. Higher objectively-assessed MVPA (p = 0.03) and steps/day (p = 0.07) at 12-week follow-up was also observed in the PAC + F group compared with the PAC group. Most (>80%) of the PAC + F group reported high levels of Fitbit use and considered the device to be beneficial for physical activity maintenance.

Conclusions

Findings suggest that activity trackers show promise as an effective, feasible and acceptable approach to support physical activity maintenance following completion of a supervised exercise intervention.

Trial registration

Prospectively registered on the Australian and New Zealand Clinical Trials Registry (ANZCTR, Trial registration number: ACTRN12616000954426).

Section snippets

Practical implications

  • Provision of supervised exercise is insufficient for many breast cancer survivors in maintaining sufficient levels of physical activity longer term.

  • Physical activity trackers may be a useful, complementary tool to supervised exercise and physical activity counselling for supporting longer term behaviour change.

  • When using physical activity trackers to support physical activity maintenance, allied health professionals need to work with the patient to ensure they understand how the activity

Methods

This study involved a convenience sample of participants who had recently completed participation in a randomised controlled exercise intervention study (the SAFE trial, trial registration number: ACTRN12616000547448). The SAFE trial (n = 60) evaluated the effect of a 12-week intervention, with a weekly exercise target of 150 min of combined aerobic- and resistance-based exercise at moderate to high intensity, delivered over five (n = 30) or 20 (n = 30) supervised sessions (depending on randomisation)

Results

Fifty-four participants completed the SAFE trial and were eligible for entry into this follow-up study (Supplementary Fig. S1). Of these, two women refused consent (declined to participate due to disease progression, n = 1; declined to participate due to commencing new treatment, n = 1). A total of 52 women consented, completed baseline assessment and were subsequently randomised into the PAC + F or PAC group (Supplementary Fig. S1). Baseline demographic and clinical characteristics between the SAFE

Discussion

These findings suggest that those who received an activity tracker, alongside a one-off physical activity counselling session, had, on average, higher physical activity levels at 12-week follow-up, compared with participants who did not receive an activity tracker. Further, nearly two-thirds (64%) of those who did not receive the activity tracker showed clinically relevant reductions in their physical activity during the 12-week follow-up period, with the mean reduction in S-MVPA estimated at 81

Conclusion

The positive, albeit preliminary findings, highlight that activity trackers may be a cost-effective and feasible strategy for promotion of longer-term physical activity. As newer models of physical activity devices are released on the market regularly, with newer devices typically including innovative technology and features (e.g. extended battery life, individualised goal-setting) and updated designs, their potential for making a difference to physical activity levels may continue to improve.

Acknowledgements

We would like to acknowledge the contributions of the women participating in SAFE and SAFE-Maintain — without their willingness to participate these studies would not have possible. SH is supported by a research fellowship from the Cancer Council Queensland.

References (33)

  • L.C. Spark et al.

    Physical activity and/or dietary interventions in breast cancer survivors: a systematic review of the maintenance of outcomes

    J Cancer Surviv

    (2013)
  • NDP Group Research

    Wearable tech device awareness surpasses 50 percent among us consumers, according to NDP

    (2014)
  • S.M. Phillips et al.

    Breast cancer survivors’ preferences for technology-supported exercise interventions

    Support Care Cancer

    (2017)
  • Wearable Inc

    Best fitness trackers 2016: Fitbit, Garmin, Misfit and more

    (2016)
  • D. Rosenberg et al.

    Acceptability of Fitbit for physical activity tracking within clinical care among men with prostate cancer

    AMIA Annu Symp Proc

    (2016)
  • J.A. Mendoza et al.

    A Fitbit and Facebook mHealth intervention for promoting physical activity among adolescent and young adult childhood cancer survivors: a pilot study

    Pediatr Blood Cancer

    (2017)
  • Cited by (20)

    • Effect and feasibility of wearable physical activity trackers and pedometers for increasing physical activity and improving health outcomes in cancer survivors: A systematic review and meta-analysis

      2022, Journal of Sport and Health Science
      Citation Excerpt :

      Intervention durations ranged between 4 weeks41,60 and 1 year53 (median = 12 weeks). Most trials (n = 25, 71%) involved pedometer-based physical activity interventions,35,37–45,49, 50,52,53,55–57,60–62,64,65,67,69,70 7 trials (20%) involved Fitbit-based interventions,46,47,54,58,59,63,66 and 3 trials (9%) involved other wearable physical activity trackers (Polar36,51 and Garmin48). Intervention goals most commonly involved performing 30 min of low-to-moderate-intensity exercise (e.g., walking) at least 5 days/week38–40,42–45,52,62 or 150 min/week of moderate-intensity physical activity.36,41,46,47,49,50,54,63,67

    • Motivational strategies to improve adherence to physical activity in breast cancer survivors: A systematic review and meta-analysis

      2021, Maturitas
      Citation Excerpt :

      Overall, intervention group involved in meta-analysis can be categorized into three groups consisting of 1) pedometer + counselling, 2) pedometer + MI, and 3) pedometer + print material. Nine trials [37, 47, 50, 51, 53, 56-58, 60] were included in meta-analysis of MVPA duration (minutes per week). There was significant heterogeneity between studies (I2 =77%).

    • Wearable activity trackers for promoting physical activity: A systematic meta-analytic review

      2021, International Journal of Medical Informatics
      Citation Excerpt :

      Relatively small sample size was used in many trials (n = 30, 70 %). About half trials recruited participants with a medical condition (n = 21, 49 %), including diabetes [38,39], cardiovascular disease [40,41], peripheral artery disease [42], chronic obstructive pulmonary disease [43,44], early knee osteoarthritis [45,46], rheumatoid arthritis [47], systemic lupus erythematosus [47], and cancer [25,32,48–55]. The other half (n = 22, 51 %) did not restrict participants according to medical conditions.

    View all citing articles on Scopus
    View full text